Literature DB >> 25551236

An overview of vortioxetine.

Alan F Schatzberg, Pierre Blier, Larry Culpepper, Rakesh Jain, George I Papakostas, Michael E Thase.   

Abstract

Six clinicians provide an overview of the serotonergic antidepressant vortioxetine, which was recently approved for the treatment of major depressive disorder in adults. They discuss the pharmacologic profile and receptor-mediated effects of vortioxetine in relation to potential outcomes. Additionally, they summarize the clinical trials, which demonstrate vortioxetine's efficacy, and discuss findings related to safety and tolerability that have high relevance to patient compliance. © Copyright 2014 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25551236     DOI: 10.4088/JCP.14027ah1

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

Review 1.  Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.

Authors:  G I Papakostas; D F Ionescu
Journal:  Mol Psychiatry       Date:  2015-07-07       Impact factor: 15.992

Review 2.  Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.

Authors:  William M Greenberg; Leslie Citrome
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

3.  Has Bipolar Disorder become a predominantly female gender related condition? Analysis of recently published large sample studies.

Authors:  Bernardo Dell'Osso; Rita Cafaro; Terence A Ketter
Journal:  Int J Bipolar Disord       Date:  2021-01-04

4.  Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice.

Authors:  Li-Xin Jiang; Geng-Di Huang; Feng Su; Huali Wang; Chen Zhang; Xin Yu
Journal:  Psychopharmacology (Berl)       Date:  2020-01-18       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.